金沙检测线路js95(中国)股份有限公司-Official website

You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
公司新闻
公司新闻 创新速递 媒体报道
金沙检测线路js95:预期2022年度收入同比增长约75.8%至90.4%
2023-01-18 16:58:01

2023年1月18日,金沙检测线路js95-B(09996.HK)发布公告,2022年1月1日至12月31日期间,实现收入人民币约2.40亿-2.60亿元,同比增长约75.8%-90.4%。

收入增加主要归功于集团经导管主动脉瓣置换产品(包括第一代产品TaurusOne®及第二代可回收产品TaurusElite®)加速商业化;以及集团现有神经介入产品(包括Tethys®中间导引导管、SacSpeed®球囊扩张导管及Jasper® SS颅内可电解脱弹簧圈等)不断放量,持续贡献集团收入增长。


Top
XML 地图